Vitrolife AB is a leading global provider of medical devices and genetic testing services dedicated to the reproductive-health market. Founded in 1994, the company develops, manufactures, and distribu... Vitrolife AB is a leading global provider of medical devices and genetic testing services dedicated to the reproductive-health market. Founded in 1994, the company develops, manufactures, and distributes specialized products for in vitro fertilization (IVF) clinics, including sperm processing solutions, culture media, and advanced genetic testing to support fertility treatments worldwide. Its mission focuses on enabling IVF clinics to enhance treatment outcomes, helping patients achieve successful reproductive health results through high-quality, reliable solutions. Operating across three key geographical segments—EMEA, Americas, and APAC—with the majority of revenue from EMEA, Vitrolife AB emphasizes rigorous quality control, regulatory compliance (including CE marks and FDA clearance), and ongoing research and development in collaboration with universities and clinics. The company, headquartered in Gothenburg, Sweden, employs over 1,100 people and integrates sustainability practices, such as ISO 14001 certification for its facilities. As part of the Vitrolife Group, following the 2021 acquisition of Igenomix, it covers the entire reproductive-health journey, from embryo culture to genetic analysis, solidifying its role in advancing assisted reproduction technologies.
In 2024, Vitrolife was subject to the Corporate Sustainability Reporting Directive (CSRD)'s requirements, which mandated the company to publish EU Taxonomy disclosures.
The company reported the eligibility and alignment of Turnover, Capital Expenditure (CAPEX) and Operating Expenditure (OPEX) with the EU Taxonomy, helping assess the extent to which its business activities align with Europe's environmental sustainability goals.
Vitrolife has also provided an activity-level breakdown of its EU Taxonomy disclosures. This granular reporting enhances transparency around which economic activities of Vitrolife are considered environmentally sustainable and contribute to at least one of the six environmental objectives defined under the EU Taxonomy framework.
Metric (tonnes)
2024
2023
2022
2021 - 2017
Total Taxonomy Aligned A1 Turnover
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
0000000
Total Taxonomy Eligible A Turnover
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
0000000
Total Taxonomy Non-Eligible B Turnover
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
0000000
1.2 CE - Manufacture of electrical and electronic equipment
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
Metric (tonnes)
2024
2023
2022
2021 - 2017
Total Taxonomy Aligned A1 Opex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
0000000
Total Taxonomy Eligible A Opex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
0000000
Total Taxonomy Non-Eligible B Opex
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
0000000
1.2 CE - Manufacture of electrical and electronic equipment
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
Metric (tonnes)
2024
2023
2022
2021 - 2017
Total Taxonomy Aligned A1 Capex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
0000000
Total Taxonomy Eligible A Capex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
0000000
Total Taxonomy Non-Eligible B Capex
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
0000000
1.2 CE - Manufacture of electrical and electronic equipment
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
7.7 CCM/CCA - Acquisition and ownership of buildings
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
Limited Data Preview
You are viewing a limited preview of Vitrolife’s EU Taxonomy dataset. The full dataset, available for download, includes eligibility and alignment metrics for turnover, CAPEX, and OPEX across all EU Taxonomy categories (A1, A2, A, B, and A+B), at both aggregate and activity level, with historical coverage back to undefined.
Access Datasets, Disclosures, and Sources
pro
Remove manual data sourcing from your workflow. Subscribe to Tracenable Pro to get credits for accessing and exporting datasets and disclosures across 8,500+ companies with 10+ years of historical coverage.
Used by 1,000+ teams in finance, climate, and research
Verified Sources Behind Vitrolife’s EU Taxonomy Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Vitrolife’s data sources below and access millions more through our Disclosure Search.
a. Vitrolife's Annual Report 2024
b. Vitrolife's Annual Report 2023
Insights into Vitrolife's Revenues from Sustainable Activities
In 2024, Vitrolife reported EU Taxonomy-eligible revenues of SEK 352.40 million, representing 10% of its total turnover. Of this amount, SEK 352.40 million of Vitrolife's revenues was classified as EU Taxonomy-aligned, indicating that 10% of the revenue-generating activities undertaken by the company substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).a
How much of Vitrolife's revenue is eligible under the EU Taxonomy?
In 2024, Vitrolife reported that SEK 352.40 million of its revenue was eligible under the EU Taxonomy, representing 10% of the company's total turnover. Of this amount, SEK 352.40 million (10% of total revenue) was classified as Taxonomy-aligned. This means that 0% of Vitrolife's revenue is eligible but not aligned, indicating that these activities did not meet the technical screening criteria, failed to comply with the Do No Significant Harm (DNSH) requirements, or lacked evidence of meeting the Minimum Safeguards.a
How much of Vitrolife's eligible revenue is aligned with the EU Taxonomy?
In 2024, Vitrolife reported that SEK 352.40 million of its revenue was aligned under the EU Taxonomy, representing 10% of its total turnover.a
This moderate level of alignment indicates that Vitrolife has begun shifting toward more sustainable operations but still has considerable room to enhance its green offerings.
Vitrolife's Eligibility & Alignment Overview
Vitrolife's Contribution to Environmental Objectives
Total Taxonomy Aligned A1 Turnover
Total Taxonomy Eligible but Not Aligned A2 Turnover
How is Vitrolife's taxonomy-aligned revenue distributed across the EU environmental objectives?
In 2024, Vitrolife reported that its taxonomy-aligned revenue was distributed across the following EU environmental objectivesa:
Climate Change Mitigation: 0%
Climate Change Adaptation: 0%
Sustainable Use and Protection of Water and Marine Resources: 0%
Transition to a Circular Economy: 10%
Pollution Prevention and Control: 0%
Protection and restoration of biodiversity and ecosystems: 0%
How much revenue does Vitrolife earn from selling climate-related solutions ?
In 2024, Vitrolife reported that SEK 0 of its total revenue was associated with activities contributing to the EU taxonomy climate-related objectives (Climate Change Mitigation and Climate Change Adaptation). This accounted for 0% of the company's total revenue,indicating that Vitrolifehas limited exposureon solutions that support climate action through its commercial activities.a
Insights into Vitrolife's CAPEX from Sustainable Activities
In 2024, Vitrolife reported EU Taxonomy-eligible CAPEX of SEK 106.70 million,representing 26% of its total CAPEX. Of this amount, SEK 45.50 million of Vitrolife's CAPEX was classified as EU Taxonomy-aligned, indicating that 11% of the company's investments were directed toward economic activities that substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).a
How much of Vitrolife's capital expenditure (CAPEX) is eligible under the EU Taxonomy?
In 2024, Vitrolife reported that SEK 106.70 million of its capital expenditure (CAPEX) was eligible under the EU Taxonomy, representing 26% of the company's total CAPEX. Of this amount, SEK 45.50 million (11% of total CAPEX) was classified as Taxonomy-aligned. This means that 15% of Vitrolife's CAPEX is eligible but not aligned, indicating that these investments either did not meet the technical screening criteria, failed to comply with the Do No Significant Harm (DNSH) requirements, or lacked evidence of meeting the Minimum Safeguards (MSS).a
How much of Vitrolife's eligible CAPEX is aligned with the EU Taxonomy?
In 2024, Vitrolife reported that SEK 45.50 million of its CAPEX was aligned under the EU Taxonomy, representing 11% of its total capital investment.a
This moderate level of alignment indicates that Vitrolife is beginning to transition its capital allocation toward greener investments, but still retains substantial opportunities for further alignment with sustainability goals.
Vitrolife's Eligibility & Alignment Overview
Vitrolife's Contribution to Environmental Objectives
Total Taxonomy Aligned A1 Capex
Total Taxonomy Eligible but Not Aligned A2 Capex
How is Vitrolife's taxonomy-aligned CAPEX distributed across the EU environmental objectives?
In 2024, Vitrolife reported that its taxonomy-aligned capital expenditure (CAPEX) was distributed across the following EU environmental objectivesa:
Sustainable Use and Protection of Water and Marine Resources: 0%
Transition to a Circular Economy: 6%
Pollution Prevention and Control: 0%
Protection and restoration of biodiversity and ecosystems: 0%
How much Vitrolife is investing in climate-related solutions?
In 2024, Vitrolife allocated SEK 0 of its CAPEX to activities contributing to the EU Taxonomy's climate-related objectives (Climate Change Mitigation and Climate Change Adaptation). This represented 0% of the company's total capital expenditure,indicating that Vitrolifehas only marginally directed its capital expenditure toward climate-related activities, suggesting limited alignment with climate objectives.a
Insights into Vitrolife's OPEX from Sustainable Activities
In 2024, Vitrolife reported EU Taxonomy-eligible OPEX of SEK 40.50 million,representing 27% of its total operating expenses (OPEX). Of this amount, SEK 40.50 million of Vitrolife's OPEX was classified as EU Taxonomy-aligned, indicating that 27% of the company's operating expenses were directed toward economic activities that substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).a
How much of Vitrolife's operational expenditure (OPEX) is eligible under the EU Taxonomy?
In 2024, Vitrolife reported that SEK 40.50 million of its operational expenditure (OPEX) was eligible under the EU Taxonomy, representing 27% of the company's total OPEX. Of this amount, SEK 40.50 million (27% of total OPEX) was classified as Taxonomy-aligned. This means that 0% of Vitrolife's OPEX is eligible but not aligned, indicating that these expenditures either did not meet the technical screening criteria, failed to comply with the Do No Significant Harm (DNSH) requirements, or lacked evidence of meeting the Minimum Safeguards (MSS).a
How much of Vitrolife's eligible OPEX is aligned with the EU Taxonomy?
In 2024, Vitrolife reported that SEK 40.50 million of its OPEX was aligned under the EU Taxonomy, representing 27% of its total operational expenditure.a
This moderate level of alignment indicates that Vitrolife is beginning to shift operational priorities toward greener practices, with room for deeper integration.
Vitrolife's Eligibility & Alignment Overview
Vitrolife's Contribution to Environmental Objectives
Total Taxonomy Aligned A1 Opex
Total Taxonomy Eligible but Not Aligned A2 Opex
How is Vitrolife's taxonomy-aligned OPEX distributed across the EU environmental objectives?
In 2024, Vitrolife reported that its taxonomy-aligned operational expenditure (OPEX) was distributed across the following EU environmental objectivesa:
Climate Change Mitigation: 0%
Climate Change Adaptation: 0%
Sustainable Use and Protection of Water and Marine Resources: 0%
Transition to a Circular Economy: 27%
Pollution Prevention and Control: 0%
Protection and restoration of biodiversity and ecosystems: 0%
How much of Vitrolife's operational budget supports climate-related solutions?
In 2024, Vitrolife allocated SEK 0 of its OPEX to activities contributing to the EU Taxonomy's climate-related objectives (Climate Change Mitigation and Climate Change Adaptation). This represented 0% of the company's total OPEX,indicating that Vitrolifehas only a limited share of operational expenditure aligned with climate goals, signaling early-stage or minimal integration of climate objectives into its routine activities.a
Want Full Access to Vitrolife's EU Taxonomy Dataset?
b
a
b
a
a
a
a
a
a